Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 1
1967 2
1968 1
1969 2
1970 1
1972 1
1974 2
1975 3
1976 4
1977 2
1978 4
1979 1
1980 1
1981 4
1982 6
1983 7
1984 9
1985 5
1986 4
1987 7
1988 6
1989 8
1990 4
1991 8
1992 12
1993 5
1994 11
1995 10
1996 7
1997 8
1998 8
1999 13
2000 9
2001 6
2002 6
2003 9
2004 17
2005 16
2006 11
2007 12
2008 12
2009 9
2010 8
2011 7
2012 8
2013 11
2014 9
2015 10
2016 13
2017 8
2018 7
2019 14
2020 12
2021 12
2022 19
2023 13

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Namba Y, Sumiyoshi N, Nakagawa K. Sugawara S, et al. Among authors: namba y. Ann Oncol. 2021 Sep;32(9):1137-1147. doi: 10.1016/j.annonc.2021.06.004. Epub 2021 Jun 15. Ann Oncol. 2021. PMID: 34139272 Free article. Clinical Trial.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. Among authors: namba y. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Free PMC article. Clinical Trial.
Advanced lipid technology.
Maeda N, Ikeda K, Matsumoto M, Namba Y. Maeda N, et al. Among authors: namba y. J Liposome Res. 2017 Sep;27(3):221-227. doi: 10.1080/08982104.2016.1224898. Epub 2016 Oct 9. J Liposome Res. 2017. PMID: 27572825 Review.
On soluble mediators of immunologic regulation.
Waksman BH, Namba Y. Waksman BH, et al. Among authors: namba y. Cell Immunol. 1976 Jan;21(1):161-76. doi: 10.1016/0008-8749(76)90337-3. Cell Immunol. 1976. PMID: 55309 Review. No abstract available.
Long-circulating liposomes.
Oku N, Namba Y. Oku N, et al. Among authors: namba y. Crit Rev Ther Drug Carrier Syst. 1994;11(4):231-70. Crit Rev Ther Drug Carrier Syst. 1994. PMID: 7664348 Review.
[ApoE].
Namba Y. Namba Y. Nihon Rinsho. 2004 Apr;62 Suppl 4:202-5. Nihon Rinsho. 2004. PMID: 15174671 Japanese. No abstract available.
Seventh BHD international symposium: recent scientific and clinical advancement.
Woodford MR, Andreou A, Baba M, van de Beek I, Di Malta C, Glykofridis I, Grimes H, Henske EP, Iliopoulos O, Kurihara M, Lazor R, Linehan WM, Matsumoto K, Marciniak SJ, Namba Y, Pause A, Rajan N, Ray A, Schmidt LS, Shi W, Steinlein OK, Thierauf J, Zoncu R, Webb A, Mollapour M. Woodford MR, et al. Among authors: namba y. Oncotarget. 2022 Jan 20;13:173-181. doi: 10.18632/oncotarget.28176. eCollection 2022. Oncotarget. 2022. PMID: 35070081 Free PMC article.
403 results